MARKET

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.240
-0.140
-5.88%
Closed 17:02 09/24 EDT
OPEN
2.340
PREV CLOSE
2.380
HIGH
2.350
LOW
2.180
VOLUME
291.60K
TURNOVER
--
52 WEEK HIGH
5.66
52 WEEK LOW
0.6153
MARKET CAP
47.82M
P/E (TTM)
-0.9091
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences
FLORHAM PARK, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating
GlobeNewswire · 09/08 20:05
PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series
FLORHAM PARK, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its
GlobeNewswire · 08/31 12:30
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 12:18
PDS Biotechnology Q2 EPS $(0.19) Beats $(0.23) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 74.67 percent increase over losses of $(0.75) per share from
Benzinga · 08/13 10:05
PDS Biotechnology reports Q2 results
PDS Biotechnology (PDSB): Q2 GAAP EPS of -$0.19.Cash and cash equivalents of $16.9MShares +0.34% PM.Press Release
Seekingalpha · 08/13 10:02
PDS Biotech Prices 6M Share Common Stock Offering $2.75/Share
Benzinga · 08/11 13:09
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 08/11 12:20
PDS Biotechnology shares are trading lower after the company announced a proposed public offering of common stock on Monday.
Benzinga · 08/11 10:32
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PDSB. Analyze the recent business situations of PDS Biotechnology Corporation through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PDSB stock price target is 7.32 with a high estimate of 10.00 and a low estimate of 5.45.
EPS
Institutional Holdings
Institutions: 43
Institutional Holdings: 6.70M
% Owned: 31.40%
Shares Outstanding: 21.35M
TypeInstitutionsShares
Increased
4
389.44K
New
15
-299.34K
Decreased
3
20.11K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
Stephen Glover
President/Chief Executive Officer/Director
Frank Bedu-Addo
Chief Financial Officer
Michael King
Chief Scientific Officer
Gregory Conn
Other
Lauren Wood
Director
Ilian Iliev
Independent Director
Kamil Ali-Jackson
Independent Director
DeLyle Bloomquist
Independent Director
Gregory Freitag
Independent Director
Richard Sykes
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PDSB
PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of PDS Biotechnology Corp stock information, including NASDAQ:PDSB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDSB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDSB stock methods without spending real money on the virtual paper trading platform.